Malaria exacts a deadly toll on human populations worldwide. A new era in the fight against the disease has seen multiple malaria vaccines entering or completing advanced clinical study 1 , including mTBVs 2 . Malaria transmission requires the establishment of Plasmodium in the Anopheles mosquito, in a manner contingent on the parasite's ookinete stage successfully traversing the midgut epithelium to initiate sporogonic development 3, 4 . TBVs disrupt this obligatory step in the parasite's life cycle 5 , limiting the number of infectious mosquito vectors and introducing local herd immunity 6 . The concept of mTBVs is simple: antibodies against specific mosquito-midgut antigens circulating in the peripheral blood are ingested by mosquitoes during feeding on immunized hosts. These antibodies, as well as complement, can survive in the mosquito midgut for up to 24 h after blood feeding and can prevent parasite access to host ligands that mediate midgut cell adhesion and invasion. Parasites are thus unable to establish infection in the vector, and the progression of parasite development and transmission to new human hosts is arrested or reduced.
a r t i c l e s
Malaria exacts a deadly toll on human populations worldwide. A new era in the fight against the disease has seen multiple malaria vaccines entering or completing advanced clinical study 1 , including mTBVs 2 . Malaria transmission requires the establishment of Plasmodium in the Anopheles mosquito, in a manner contingent on the parasite's ookinete stage successfully traversing the midgut epithelium to initiate sporogonic development 3, 4 . TBVs disrupt this obligatory step in the parasite's life cycle 5 , limiting the number of infectious mosquito vectors and introducing local herd immunity 6 . The concept of mTBVs is simple: antibodies against specific mosquito-midgut antigens circulating in the peripheral blood are ingested by mosquitoes during feeding on immunized hosts. These antibodies, as well as complement, can survive in the mosquito midgut for up to 24 h after blood feeding and can prevent parasite access to host ligands that mediate midgut cell adhesion and invasion. Parasites are thus unable to establish infection in the vector, and the progression of parasite development and transmission to new human hosts is arrested or reduced.
We have shown that AnAPN1, an alanyl aminopeptidase N (APN) present on the apical surface of the Anopheles gambiae midgut, is a potent mTBV candidate [7] [8] [9] . Importantly, parallel studies in the field, using P. falciparum collected from parasitized mosquitoes, corroborated laboratory-derived data 9 , thus demonstrating the strain-and species-transcending potency of anti-AnAPN1 antibodies. However, the role of AnAPN1 in Plasmodium infection of the mosquito gut, and how anti-AnAPN1 antibodies functionally block parasite transmission, has remained elusive. To identify cryptic AnAPN1 conformational epitopes and to gain insight into functional versus decoy vaccine domains, we solved the crystal structure of AnAPN1. Here, we describe the immunoreactivity and transmission-blocking profile of mAbs to AnAPN1, present the AnAPN1 structure and map a new transmissionblocking epitope. These findings deepen the understanding of vector-Plasmodium interactions and ultimately could fuel the continued development and optimization of the AnAPN1 mTBV.
RESULTS

Structure determination
AnAPN1 is composed of an N-terminal signal peptide (residues 1-19) and C-terminal ectodomain (residues 22-993) that contains a putative mucin O-glycosylated region (residues 952-993). A glycosylphosphatidylinositol anchor (residues 997-1020) resides at the C terminus. We determined the crystal structure of near-full-length AnAPN1 (residues 22-942) to 2.65 Å with a crystallographic R factor of 20.3% (R free of 25.4%). The crystallographic refinement statistics are reported in Table 1 . There were two AnAPN1 molecules within the asymmetric unit (molecules A and B), and superposition of the Cα backbone atoms gave an overall r.m.s. deviation of 0.26 Å. The first 35 residues and residues 531-541 could not be modeled in either molecule, owing to poor electron density. An additional disordered region included residues 826-830 in molecule A. Although we did not attempt to obtain ligand-bound AnAPN1, a peptide was coordinated within the active site of both molecules, and we modeled it according to the electron density as AAAKL and AAK for molecules A and B, respectively ( Supplementary Fig. 1a,b) . Anomalous diffraction difference maps 10 confirmed the presence of a zinc metal ion in the active site of both molecules (Supplementary Table 1 and Supplementary Fig. 1c ).
Overall structure
The tertiary structure of the AnAPN1 ectodomain (residues 57-942) exhibited the classical four-domain assembly of M1-family metallopeptidases, designated domains I-IV (Fig. 1a) . The N-terminal domain I, visible from residue 57 (residues 57-270), comprised a 15-stranded β-barrel fold, nine strands of which define the subunit vaccine immunogen (NT135aaAnAPN1; residues 60-194). Domain II, or the catalytic domain (residues 271-523), is involved in substrate recognition and contains the G 330 AMEN motif common to many exopeptidases, in addition to the zinc-binding motifs HEXXH (H 366 EYAH 370 ) and NEXFA (NE 389 GFA). This domain had a thermolysin-like fold and comprised a four-stranded β-sheet with a connecting α-helix (helix α4) and an eight-α-helix superhelix subdomain. Domain III (residues 524-613) adopted a β-sandwich architecture in which two separate antiparallel β-sheets packed together. The C-terminal domain IV (residues 614-942), as compared with other M1-family metallopeptidases, adopted the most variable conformation, and it comprised a 17-α-helix superhelix. According to a DALI structural alignment, AnAPN1 was most similar to porcine APN (PDB 4FKE 11 ; r.m.s. deviation 2.5 Å) with 32% sequence identity and 48% sequence similarity (Supplementary Fig. 2 ).
Active site access
Each AnAPN1 monomer revealed two openings to the active site (Fig. 1b,c) . The first was a large electronegative cleft, 35 Å wide, 20 Å deep and 40 Å long, that was predominantly flanked by domains II and IV and was able to access the active site. The second, located on domain IV, was a small 11-Å-diameter pore that led to a 38-Å-long channel. An analogous pore, or C-terminal channel, was previously reported for PfA-M1 (ref. 12) and was postulated to permit substrate entry, whereas that of ERAP1 was considered to be a putative C-terminal substrate-binding site 13 . Given the exposed, solvent-accessible active site, we describe AnAPN1 as adopting an open conformation like that of ERAP1 (comparison of Fig 2a and  Fig. 2b; Supplementary Fig. 3) . However, the orientation of domain IV relative to the other domains, which determines the extent of the aperture, lay between the orientations in the closed (PDB 2YD0 (ref. 13) ) and the open (PDB 3MDJ 14 ) states of ERAP1 (Fig. 2) .
This was reflected by a DALI structural alignment in which AnAPN1 had an r.m.s. deviation of 4.2 Å for the open conformation (PDB 3MDJ 14 ) and, similarly, 3.9 Å for the closed conformation (PDB 2YD0 (ref. 13) ).
The most pronounced differences between the open conformations of AnAPN1 and ERAP1 were in domain IV: specifically, four helix-loop-helix motifs (α22-α23, α24-α25, α27-α28 and α29-α30) differed in orientation (Fig. 2) . The hinge between the conformations originated between helices a r t i c l e s npg a r t i c l e s α20 and α21, with two disulfide bridges connecting helix α19 to α20 (Cys736-Cys743) and α21 to α23 (Cys772-Cys808). The bridge between α19 and α20 restricted the angle of rotation between these two helices and limited the movement of domain IV. The surface representation of AnAPN1, with a large rift between domains II and IV, was most similar to porcine APN and the open conformation of ERAP1 (comparison of Supplementary Fig. 3a and Supplementary  Fig. 3b ,c) but was distinct from human APN and closed ERAP1 (comparison of Supplementary Fig. 3a and Supplementary Fig. 3d,e) .
The active site of AnAPN1
The active site residues of AnAPN1 were within domain II (Fig. 3a) . The zinc ion was coordinated by the Nε2 atoms of His366 and His370 from the H 366 EXXH 370 motif, the carboxyl Oε of Glu389 of the NE 389 XFA motif and the N terminus of the modeled peptide (Fig. 3a,b and Supplementary Fig. 1a,b) . The N-terminal residue of this peptide was anchored to the active site, coordinated to the highly conserved Glu333 of the GAMEN motif in addition to Glu199 and Glu389. This residue also formed hydrogen bonds with His366 and the highly conserved Tyr452 (Fig. 3a,b) . Tyr452 has been proposed to stabilize the oxyanion generated in the transition state 15 . The alanine at the second position of the peptide also formed contacts with residues that lined the electronegative cleft and formed hydrogen bonds with Gly330 and Ala331 from the GAMEN motif (Fig. 3b) . The conformation of Tyr452 (equivalent to Tyr438 in ERAP1) is often used as a partial indicator of whether M1-family metalloenzymes are in an active or inactive state 13 . Tyr452 pointed toward the active site in AnAPN1 (Fig. 3c) and suggested an active enzyme conformation.
Potential for AnAPN1 dimerization
Given that solved structures of M1-family metalloenzymes have been reported to be either monomeric or dimeric, and two AnAPN1 molecules were in the AnAPN1-crystal asymmetric unit, we determined the quaternary structure of AnAPN1 in aqueous solution.
Sedimentation velocity experiments showed a single sedimenting boundary ( Supplementary Fig. 4a ), and continuous sedimentationcoefficient distribution (c(s)) ( Supplementary Fig. 4b ) showed that AnAPN1 existed primarily as a single species with a standardized sedimentation coefficient of 9.2 S. Analysis of continuous mass distribution (c(M)) ( Supplementary Fig. 4c ) revealed that this species had a molecular weight of approximately 230 kDa, which is consistent with an AnAPN1 dimer (M r of 214 kDa). Intact human aminopeptidase A and APN dimers have been observed in vivo 16, 17 . 
npg a r t i c l e s
We predicted that two molecules from adjacent asymmetric units formed a putative AnAPN1 dimer, with contacts via domains III and IV (Fig. 4 and Supplementary Table 2 ). Several salt bridges and hydrogen bonds were formed between Asp653 (domain IV) and Arg531 (domain III). Lys551 (domain III) residues from each monomer formed hydrogen bonds with each other and also formed an extensive network of hydrophobic contacts (Supplementary Table 2 ). As opposed to the dimer arrangement in the asymmetric unit, this dimer allowed free movement of domain IV into an open and closed conformation and an unobstructed cleft for peptide entry and exit. In addition, the dimer was symmetrical, buried 864 Å 2 and had a solvation free-energy gain upon dimer formation (∆ i G) of -7.9 kcal/mol (P = 0.21). Moreover peptides 1, 5, 7 and 9, discussed below, were equally solvent accessible in the monomeric versus the putative dimeric form of AnAPN1 (Fig. 4) .
Biochemical characterization of AnAPN1 activity
We verified enzymatic activity of recombinant near-full-length S2-expressed AnAPN1 (residues 22-942) with in vitro spectrophotometricbased assays by measuring the continuous increase in absorbance at 405 nm due to cleavage of the substrate l-leucine-p-nitroanilide and release of 4-nitroaniline (Fig. 5a ). We observed a pH optimum of 6.0-7.5 ( Fig. 5b) , the upper range of which is consistent with the pH in the midguts of blood-fed mosquitoes 18 . AnAPN1 was inactive in the presence of the metalloprotease inhibitor 1,10-phenanthroline ( Fig. 5c ) but was substantially activated by Co 2+ , Mn 2+ and Zn 2+ cations ( Fig. 5d-f) . We estimated the K m for l-leucine-p-nitroanilide at pH 7.5 to be 1.84 mM in the presence of 1 mM Mn 2+ (Fig. 5g ) and 5.46 mM at 10 mM Mn 2+ (Fig. 5h) .
Peptide epitope-mapping enzyme-linked immunosorbent assay
The CD spectra of the original AnAPN1-subunit vaccine immunogen (NT135aaAnAPN1) confirmed the predicted β-sheet secondary structure, given the strong negative signal at 218 nm (data not shown). The NT135aaAnAPN1 immunogen contains nine predicted β-and T-cell epitopes that were previously synthesized and probed with individual mouse, rabbit and nonhuman primate (NHP) AnAPN1 antisera by enzyme-linked immunosorbent assay (ELISA) 8 . In this study, we generated three new mAbs against this immunogen: 2A12, 2C6 and 4H5B7. As expected, all mAbs recognized NT135aaAnAPN1 (Fig. 6a) . However, of the three, only 4H5B7 and 2C6 reacted with A. gambiae-midgut lysate (Fig. 6b) , and, importantly, only 4H5B7 recognized native AnAPN1 in midgut cryosections (Fig. 6c) . We observed that 2A12 recognized peptide 1 (Supplementary Table 3 and Supplementary Fig. 5a ), whereas 4H5B7 showed weak reactivity with peptides 4 and 5 and negligible reactivity with peptide 7 (Supplementary Table 3 and Supplementary Fig. 5b ). These data suggest poor presentation of the epitope context to 4H5B7 in ELISAs. Of the three mAbs, only 4H5B7 blocked P. falciparum development in A. gambiae, at concentrations of 4-100 µg/ml (Fig. 6d) , whereas 2A12 and 2C6 had no blocking activity (Fig. 6d and Supplementary Fig. 5c ). 
npg a r t i c l e s
By immunoblot, 4H5B7 recognized both NT135aaAnAPN1 and nearfull-length AnAPN1; however for the latter, more protein was required (Supplementary Fig. 5d ). However, in a more complex sample, such as whole mosquito-midgut lysate, 4H5B7 could barely stain AnAPN1 (data not shown), thus suggesting that in immunoblots, either the linear portion of the complete conformational epitope for 4H5B7 is potentially masked by several midgut proteins of the same relative molecular mass or 4H5B7 recognizes a conformational epitope (Fig. 6c) . Polyclonal antiserum from NHPs showed strong recognition of peptide 5 and peptide 7 epitopes 8 , and 4H5B7 shared similar recognition of peptide 5, which is part of the larger peptide 7 fragment (Supplementary Table 3 and Supplementary Fig. 5b ). Although the reactivity in the peptide ELISA was low, given the high signalto-noise ratio, the data suggest that the 4H5B7 epitope is potentially located in peptide 7. We depleted peptide 5-specific antibodies from pooled NHP antiserum (post-NT135aaAnAPN1 immunization) and observed that anti-peptide 5 IgG did not confer transmission-blocking activity (Supplementary Fig. 5e ) and that weak reactivity of 4H5B7 to peptide 5 in the peptide ELISA was not correlated with 4H5B7 transmission-blocking activity. However, depletion of peptide 7-specific IgG resulted in the loss of transmission-blocking activity (Fig. 6e) . Using only 10 µg/ml of the peptide 7-specific IgG from that depletion experiment restored transmission-blocking activity (Fig. 6e) . This was surprising in that we anticipated a reduction in oocyst number because we had not depleted peptide 9-specific IgG from the pooled serum (Supplementary Table 3) , and we had previously shown that antibodies directed only to the peptide 9 epitope demonstrate potent transmission-blocking efficacy 8 . The 57% reduction in mean oocyst intensity by peptide 7-specific IgG (P = 0.31) was low in comparison to the 95% reduction by peptide 9-specific IgG (P = 3.00 × 10 −8 ); however, in a follow-up study, the reduction in mean oocyst intensity by peptide 7-specific IgG increased to 93% (Supplementary Fig. 5f ). It is possible that anti-peptide 7 IgGs may not all recognize the same critical subepitope or that IgG concentration could not be adequately controlled. In an independent study, total IgG from BALB/c mice immunized with peptide 7 significantly reduced P. falciparum oocyst intensity, by 97.5% (Supplementary Fig. 5f ). These results further suggest cooperative transmission-blocking activity between critical anti-peptide 7 and anti-peptide 9 IgG when concentrations of either IgG in total IgG antisera are too low. Furthermore, the data suggest that peptide 4, which is part of the peptide 7 epitope (Supplementary  Table 3) , is likely to be the subepitope on peptide 7 that is recognized by 4H5B7 on native AnAPN1.
Peptide 7 appears to be highly conserved across Old World and New World anophelines 8 . However, among laboratory populations of Anopheles stephensi, differences in transmission-blocking activity of mouse anti-NT135aaAnAPN1 IgG suggest nuanced polymorphisms that may exist between laboratory populations (data not shown). We therefore tested 4H5B7 activity against P. falciparum NF54 in two A. stephensi strains: NIH and Nijmegen (Supplementary Fig. 5g and h, respectively) and found equivalent blocking activity between the strains (related Source Data). Moreover, given known genetic and phenotypic differences between laboratory and field parasites, we conducted a parallel study in Cameroon to confirm our laboratory observations and observed complete transmission-blocking activity against naturally circulating strains of P. falciparum in the A. gambiae Ngousso strain (Fig. 6f) . Clearly, if only a single specific antibody at concentrations greater than 10 µg/ml against either peptide 7 or 9 are used in these assays (Fig. 6d,f and Supplementary Fig. 5f ), complete reduction in P. falciparum oocyst intensity would be expected. Unfortunately, humans 
AnAPN1 structure-based epitope mapping
The antibodies described in this study recognized peptides 1, 4, 5, 7 and 9 (Supplementary Table 3) , and thus we mapped these peptides to the AnAPN1 monomer (Fig. 7) . The 2A12 mAb appears to bind peptide 1 and, as expected, lacks any transmission-blocking activity against P. falciparum. In the AnAPN1 structure, the majority of this peptide was unstructured (residues 60-68), but residues 69-74 were within the first β-strand of domain I and were situated in a cleft formed within the β-barrel (Fig. 7a,b) . Although the unstructured portion of peptide 1 is surface exposed, ectodomain residues 20-56, almost immediately preceding peptide 1, were notably absent in the structure and may alter solvent accessibility. Accordingly, 2A12 could bind to both native NT135aaAnAPN1, according to ELISA (Fig. 6a,c) , and denatured near-full-length AnAPN1, according to western blot (data not shown). However, 2A12 did not bind native AnAPN1 in midgut lysates, according to ELISA (Fig. 6b) .
The epitope of the transmission-blocking 4H5B7 mAb mapped to peptide 7 (residues 98-123), which incorporated peptide 5 (residues 95-109) and peptide 4 (residues 107-121) (Fig. 7c,d) . Although the N-(residues 95-109) and C-terminal (residues 116 onwards) regions of peptide 7 (mapping to peptides 5 and 4, respectively) were predominantly surface exposed, the central portion sat beneath and was occluded by the β6 and β7 strands of AnAPN1 domain I ( Supplementary Fig. 2 and Fig. 7c,d ). Peptide 7 doubled back on itself and had proximal N and C termini (closest distance 7.2 Å), and this partly explains the peptide ELISA results (Fig. 7c,d ).
Peptide 9 (residues 173-194) is a transmission-blocking epitope, and anti-peptide 9 antibodies recognized the first five (residues 173-177) and the last three residues (192-194) of peptide 9 as well as native and denatured protein 8 . Peptide 9 predominantly formed a β-hairpin, with immunoreactive residues 173-176 and 192 being surface exposed and proximal to one another (Fig. 7b) . Peptide 9 flanked an opening of the active site and formed a small number of contacts with both catalytic domain II (specifically, hydrogen bonds to Asn285, Asp327 and Asp326) and domain IV, but, as previously determined, anti-peptide 9 AnAPN1 antibodies do not interfere with AnAPN1 aminopeptidase activity 8 .
APN molecules have been identified as Cry-binding proteins in lepidopteran (for example, Bombyx mori and Plutella xylostella) and dipteran (for example, A. gambiae and Aedes aegypti) species 19, 20 , thus suggesting a conserved mode of action for Cry toxins. Binding of Cry1Aa toxin to B. mori APN has been localized to residues 135-198 (B. mori numbering; NP_001037013.1) 21 , a region proposed to be a common Cry-binding region in other APN isoforms 22, 23 . We mapped the Cry-binding region of B. mori onto the AnAPN1 structure. Intriguingly, the homologous Cry-binding region entirely encompassed peptide 9 and directly abutted the two surface-exposed regions of peptide 7, particularly the peptide 4 subepitope (Fig. 7e,f and Supplementary Fig. 6 ). This structure-guided observation provides a link between the two somewhat-distal transmissionblocking epitopes within domain I (peptides 7 and 9) and suggests that transmission-blocking anti-APN1 antibodies function by sterically hindering the binding of a Plasmodium pore-forming protein.
DISCUSSION
Malaria remains an unabated global health burden, and its eradication requires the development of tools and interventions such as TBVs. To maximize investment in TBVs, fundamental knowledge of immunogen structure is paramount, including identification of neutralizing, polymorphic and decoy epitopes that in turn can inform rational, efficacious vaccine design [24] [25] [26] .
To our knowledge, we are the first to report the three-dimensional structure and enzymatic characterization of APN1 from adult A. gambiae. The protein's overall structure resembled that of APNs from other species and exhibited classic four-domain architecture. The active site, accessible to solvent and containing a peptide, was open, with residue Tyr452 assuming a catalytically active position. X-ray fluorescence scans of the crystal revealed the presence of a zinc metal ion in the active site, and we confirmed divalent cation-mediated activation in vitro. Because AnAPN1 was crystallized at pH 9.7, and despite the inward-facing orientation of Tyr452, we propose that the AnAPN1 structure resembles a catalytically inactive state. This is supported by biochemical experiments with recombinant AnAPN1, which we found to be optimally active at pH 6.0-7.5, and evidence that the adult midgut at steady state has a pH range of 8.0-9.5 but is seldom above pH 10 (ref. 27) . AnAPN1 is structurally most similar to porcine APN, including the orientation and placement of the highly variable domain IV, which influences the degree to which the active site cleft opens. Despite similarities in the solvent exposure of the porcine and AnAPN1 active sites, porcine APN1 was previously reported to be in the closed form and active, on the basis of mutagenesis studies, the observed conformation of the Tyr452-equivalent residue within the active site and the pH of crystallization 16 . Overall, Figure 7 Location of predicted B-and T-cell epitopes on domain I of AnAPN1. Peptides 1, 7 and 9 are shown in pink, purple and green, respectively, in cartoon (a) and surface (b) representation. The surfaceexposed residues of the first five residues (blue) and the last three residues (red) of peptide 9 are labeled. Peptides 4 and 5, which together form peptide 7, are shown in orange and yellow, respectively, in cartoon (c) and surface (d) representation. Equivalent residues of the Cry1Aa toxin-binding site on B. mori ( Supplementary Fig. 6 ) are mapped onto AnAPN1 in both cartoon (e) and surface (f) representation and are shown in cyan. The Cry1Aa toxin-binding site overlaps peptide 9 and is situated alongside peptide 7. Peptide 1 is shown in pink for reference. npg a r t i c l e s these two studies highlight the need to exercise caution in assigning APN enzymes, which are capable of adopting transient and intermediate states, to an open or closed state in which the enzyme is inactive or active, respectively. In further support of this notion, an inward-facing active site tyrosine is not necessarily synonymous with catalytic activity. Sedimentation velocity experiments confirmed that recombinant AnAPN1 (spanning residues 22-945) is a dimer in aqueous solution. Our predicted dimer has characteristics typical of biological assemblies, such as symmetry, a large buried surface area and a statistically significant ∆ i G value 28, 29 . Importantly, in the dimer configuration, all peptides relevant to this study, including peptides 1, 4, 5, 7 and 9, were exposed. None of the potential dimer interfaces observed in the AnAPN1 crystal structure corresponded to previously published aminopeptidase A or APN dimers; however, each published structure is also distinct 16, 17, 30 . The absence of the N-terminal 35 residues of the AnAPN1 ectodomain makes it difficult to predict the orientation of a putative AnAPN1 dimer on the membrane. Nevertheless, the structure defines the atomic coordinates of transmission-blocking AnAPN1 epitopes identified in this study, an essential step toward optimizing the AnAPN1 mTBV.
The 4H5B7 mAb blocked parasite development in mosquitoes at low concentrations and, similarly to NHP antiserum, focused reactivity to peptides 5 and 7, according to ELISA. The peptide ELISA is very sensitive, but it does not quantify the concentration of specific IgG to a given linearized peptide in total IgG, and it cannot capture antibodies against conformation-dependent epitopes, nor can it predict functional activity. As a result, we observed that a strong NHP IgG response to peptide 5 or the mAb 2A12 response to peptide 1 in this assay did not correlate with blocking activity. This was further borne out in our use of 2A12 as an isotype-matched control IgG in the standard membrane feeding assays (SMFAs). Moreover, we would have predicted that a strong peptide 7 and peptide 9 response in the assay would not have resulted in a reduction in blocking activity when only peptide 7-specific IgG was depleted. These results suggest that peptides 1 and 5 are highly immunogenic decoy epitopes. Fortunately, the NHP-recognition profile and transmission-blocking activity as a whole also suggest that peptide 7 alone can be targeted in different ways by antibodies and that IgG may be potentially directed to different subepitopes of peptide 7, beyond the arbitrary selection of peptides 4 and 5. Given that only some peptide 7 residues are exposed, the structure suggests that new subepitopes straddling peptides 4 and 5 may be recognized. The data also support the notion that the mechanism underlying the potent transmission-blocking activity of 4H5B7 is the recognition of a conformation-dependent epitope that is predominantly found on peptide 4. This is important to know because peptide 4 was previously predicted to be an immunogenic hotspot for a human humoral response 8 . By using the structure of AnAPN1, we reveal that peptides 7 and 9 map to the same surface of AnAPN1 but make no direct contacts and that cooperative binding of antibodies to these epitopes is critical for maximal transmission-blocking efficacy.
Bacillus thuringiensis Cry toxins form pores in mosquito-larval midguts, a process likely to involve receptors such as cadherins, alkaline phosphatases, glucosidases and aminopeptidases 20, [31] [32] [33] [34] [35] [36] . The B. thuringiensis Cry1Aa toxin-binding region of B. mori APN was previously localized and predicted to be a common Cry-binding region in APN isoforms. We mapped the predicted region onto the AnAPN1 structure 21, 23 . The Cry-binding region completely encompassed peptide 9 and sat adjacent to peptide 4, thus potentially linking these transmission-blocking epitopes. Although a portion of the Cry-binding region sits adjacent to peptide 5, antibodies to the peptide 5 subepitope do not have any blocking activity, presumably because they are distant from the main site. Because Cry proteins are pore-forming toxins, we predict that antibodies to peptides 4 and 9 block an ookinete micronemal pore-forming protein, which is a member of the Plasmodium perforin-like protein family [37] [38] [39] [40] . This would prevent the protein from binding AnAPN1 and would critically influence transmission by essentially preventing pore formation in the midgut during cell invasion. In support of this hypothesis, antibodies to peptide 1, again remote from the aforementioned binding site, do not block P. falciparum, nor does the peptide 1-binding mAb 2A12 (ref. 8) .
Outbred mice are known to generate a vigorous humoral response to NT135aaAnAPN1 that is devoid of anti-peptide 7 or anti-peptide 9 antibodies, and, as would be expected, these antisera fail to block P. falciparum transmission 8 . Given that both peptides 1 and 5 are immune-decoy epitopes in outbred mice and in NHPs, current immunogen design must now be reexamined. Preclinical studies predominantly depend on mouse immunization studies to generate evidence to inform 'go or no-go' decisions. We anticipate that in future studies of our candidate mTBV antigen, ELISAs that demonstrate a robust humoral response after immunization of outbred animals (including humans) will only confirm what is already known about AnAPN1's potent immunogenicity; however, such data have poor predictive value for functional activity. The structure-guided mapping of transmission-blocking epitopes on AnAPN1 suggests that the next-generation AnAPN1 immunogen should preclude peptides 1 and 5 and should shift the B-cell epitope window to immunofocus the humoral immune response to what we predict is a larger neoepitope comprising the subepitope peptides 7 and 9.
METHODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METHODS
Cloning, expression and purification of near-full-length AnAPN1. The nearfull-length coding sequence of A. gambiae AnAPN1 was amplified from midgut cDNA (pMTAPN1F 5′-TACCTACCATGGCCGCCATACAAGAGTAGTGGA-3′ and pMTAPN1R 5′-GATATGGCGGCCGCCTCGGCTAGGAAGTTGGACAG-3′) and cloned into the pMT-Bip-V5-His C Drosophila expression vector with NcoI and NotI restriction enzymes. Drosophila S2 cells (Life Technologies) were stably transfected with the expression vector with Effectene Transfection Reagent (Qiagen) and grown in the presence of hygromycin B (300 µg/mL). Expression was induced upon addition of copper sulfate (600 µM), and near-full-length recombinant AnAPN1 (rFL-APN1) was recovered from the supernatant 24 h later by concentration with PEG 8000 in Spectra/Por 2 dialysis sacks (molecularweight cutoff of 12-14 kDa) (Spectrum Labs). The protein was subsequently purified with Ni-NTA agarose (Qiagen). For further purification, 50 µl of recombinant protein was directly injected onto a Bio SEC-3 (Agilent, 150 Å, 7.8 × 300 mm) HPLC size-exclusion column equilibrated with 150 mM sodium phosphate, pH 7.0 ( Supplementary Fig. 7) ; this was followed by buffer exchange into 10 mM Tris, pH 7.5, and 150 mM NaCl, with a 3-kDa Amicon filter (EMD Millipore). Purity was assessed via SDS-PAGE, and purified AnAPN1 was subsequently used in functional analyses and crystallization trials.
Enzymatic characterization of the near-full-length, S2-expressed AnAPN1. Aminopeptidase assays were performed as described previously 41, 42 , with a final concentration of 50 nM recombinant near-full-length AnAPN1 and 1 mM of l-leucine-p-nitroanilide (Sigma) in a total volume of 200 µl of APN buffer (10 mM Tris-HCl, pH 7.5, and 150 mM NaCl) at 25 °C, unless described otherwise. Activity was measured spectrophotometrically by monitoring the continuous increase in absorbance at 405 nm due to the release of 4-nitroaniline every 30 s over the course of 30 min. For determination of pH optimum, activity was measured in APN buffer adjusted to a pH between 6.0 and 9.5. The ability of various metal cations to reactivate AnAPN1 was determined after 1-h incubation at room temperature with 10 mM 1,10-phenanthroline at final ion concentrations of 1 mM and 10 mM. The effect of cobalt(ii), magnesium(ii), and zinc(ii) ions to reactivate AnAPN1 activity after incubation with 10 mM 1,10-phenanthroline was measured over a range of ion concentrations from 0-10 mM. Kinetics of AnAPN1 activity was determined in the presence of either 1 mM or 10 mM MnCl 2 for a range of l-leucine-p-nitroanilide concentrations (0-4 mM).
Crystallization. Crystals of near-full-length AnAPN1 (residues 22-942) were grown at 21 °C with the hanging-drop vapor-diffusion method. Crystals grew at 9.5 mg/mL in 0.1 M CHES, pH 9.7, and 22% (w/v) PEG 8000. Crystals, preequilibrated in crystallization solution containing 15% (v/v) glycerol as the cryoprotectant, were flash-cooled in a liquid-nitrogen stream at -163 °C.
Structure determination and refinement. Data were collected (λ = 0.954, -163 °C) from a single crystal with an ADSC Q315r CCD detector on the MX2 microcrystallography beamline at the Australian Synchrotron. The data were integrated and scaled with MOSFLM 43 and SCALA, respectively, both within the CCP4 suite 44 . The crystals belong to space group P2 1 2 1 2 1 , with unit-cell dimensions a = 113.48 Å, b = 132.90 Å, c = 146.01 Å, and α = β = γ = 90°, results consistent with two AnAPN1 molecules per asymmetric unit. The structure of AnAPN1 was determined by molecular replacement with PHASER 45 with uncomplexed porcine aminopeptidase-N (PDB 4FKE 11 ) as the search model. Refinement of the AnAPN1 model to 2.65 Å was performed in REFMAC5 (ref. 46 ) with iterative cycles of manual model building in COOT 47 . The quality of the model was monitored by the R free value, which represented 5% of the data. The structure was validated with the MolProbity server 48 , and figures were created with PyMOL (http://www.pymol.org/). Ramachandran statistics showed 94% of residues in the most favored region, 4% in the additionally allowed regions and 1% in the disallowed region. Details of data-processing statistics and final refinement values are summarized in Table 1 .
Identification of active site metal ion. An X-ray fluorescence scan (5.5-15.5 keV) was performed to identify metal ions within the crystal. Both zinc and copper were identified, so complete anomalous diffraction data were collected at either end of the K-absorption edge for both Zn (λ = 1.281, 1.286) and Cu (λ = 1.378, 1.384) (Supplementary Table 1) . Element-specific anomalousdifference DANO maps were calculated with both data sets and the CCP4-supported program FFT 10 .
Analytical ultracentrifugation. Sedimentation velocity experiments were performed in a Beckman Coulter model XL-I analytical ultracentrifuge. Doublesector quartz cells were loaded with 400 µL of buffer (10 mM Tris, pH 7.5, and 150 mM NaCl) and 380 µL AnAPN1 at an initial concentration of 0.15 mg/mL. The cells were loaded into an An50-Ti rotor and left to equilibrate at 20 °C. Initial scans were performed at 3,000 r.p.m. to determine the optimal wavelength and radial positions for the experiment. Absorbance readings were subsequently collected every two minutes at 230 nm and 40,000 r.p.m. at 20 °C. Solvent density, solvent viscosity and estimates of the partial specific volume of AnAPN1 (0.7325 mL/g) at 20 °C were calculated with SEDNTERP 49 . Data were analyzed with c(s) and c(M) with SEDFIT 50, 51 .
Production of monoclonal and polyclonal antibodies. A panel of monoclonal antibodies were generated after immunization of female BALB/c mice (n = 10) with Escherichia coli-expressed 135-amino acid N-terminal AnAPN1 (NT135aaAnAPN1) at GenScript (Piscataway, New Jersey, USA) according to their proprietary protocol. Three hybridomas were produced, and the secreted antibodies were analyzed as described below. Five female Swiss Webster mice (6-8 weeks of age) were immunized with incomplete Freund's adjuvant (IFA) as a control, or NT135aaAnAPN1 (n = 10) were primed via subcutaneous injection and boosted three times at 2-week intervals via intraperitoneal injection with 5 µg/mL of NT135aaAnAPN1 in 15% sucrose, 10 mM Tris, pH 7.85, and 0.2% Tween 80 (ST/T80 buffer) emulsified (1:1) in IFA, as described previously 8 . All mouse studies were approved by the Johns Hopkins Animal Care and Use Committee (MO12H232).
Nonhuman-primate immunizations. Four ten-year-old female Macaca mulatta (India strain) NHPs were primed and boosted at 28 and 70 d after priming with recombinant NT135aaAnAPN1 (0.1 mg/mL) in ST/T80 buffer, formulated with Alhydrogel (0.8 mg/mL) via intramuscular injection, as previously described 8 . NHP experiments were approved by the Johns Hopkins Animal Care and Use Committee (PR11H18). Anti-AnAPN1 serum titers were determined for each individual animal at various time points during the immunization regimen by ELISA.
BALB/c mouse immunizations.
Five female BALB/c mice (7 weeks of age) were primed subcutaneously and subsequently boosted via intraperitoneal injection three times at 2-week intervals with 5 µg/mL peptide 7 conjugated (1:1) in PBS with keyhole limpet hemocyanin (KLH) in a 1:1 emulsion with IFA. Five additional control mice were primed and boosted with 5 µg KLH in PBS emulsified 1:1 with IFA. Serum collected 2 weeks after the final boosting immunization was pooled for purification of total IgG. ELISA and western blot assays. For ELISAs, 96-well MaxiSorp microtiter plates (Nunc, Fisher Scientific) were coated with the NT135aaAnAPN1 or A. gambiaemidgut lysate as previously described 8 . The optical density (OD at 450 nm) and reciprocal serum dilutions were measured on a Molecular Devices absorbance microplate reader. Endpoint titers were defined as the highest reciprocal serum dilution giving an OD reading greater than that of preimmune serum plus three s.d. For immunoblots, NT135aaAnAPN1 or the near-full-length S2-expressed AnAPN1 were resolved on a 4-20% Tris-glycine SDS-PAGE gel and transferred to nitrocellulose membrane. The blot was incubated with 4H5B7 mAb (30 µg/mL) overnight at 4 °C and then detected with goat anti-mouse IgG 680LT Ab (1:50,000; cat. no. 926-68020, Li-Cor) for 1 h at room temperature with the Li-Cor Odyssey Near-infrared imager (Li-Cor). Peptide epitope-mapping ELISAs were performed as described 8 .
Peptide-specific antibody purification. Protein G purified from pooled NHP IgG was fractionated for peptide 5, 7 and 9-specific IgG by affinity chromatography with iodoacetyl coupling resin (Pierce) coupled to 1 mg of peptide. IgG was quantified by BCA protein assay (Pierce). 
